HK1170737A1 - 萘啶衍生物及其作為激酶抑制劑的用途 - Google Patents

萘啶衍生物及其作為激酶抑制劑的用途

Info

Publication number
HK1170737A1
HK1170737A1 HK12111592.5A HK12111592A HK1170737A1 HK 1170737 A1 HK1170737 A1 HK 1170737A1 HK 12111592 A HK12111592 A HK 12111592A HK 1170737 A1 HK1170737 A1 HK 1170737A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
naphthyridine derivatives
naphthyridine
derivatives
kinase
Prior art date
Application number
HK12111592.5A
Other languages
English (en)
Inventor
．舒斯特
．格拉齊
．塞佩爾特
．波利莫羅普洛斯
．穆勒
．京特
．馬爾尚
．德福
Original Assignee
阿特納贊塔裡斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿特納贊塔裡斯有限公司 filed Critical 阿特納贊塔裡斯有限公司
Publication of HK1170737A1 publication Critical patent/HK1170737A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12111592.5A 2009-11-26 2012-11-15 萘啶衍生物及其作為激酶抑制劑的用途 HK1170737A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09177132A EP2332939A1 (en) 2009-11-26 2009-11-26 Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
US26471109P 2009-11-27 2009-11-27
PCT/EP2010/068119 WO2011064250A1 (en) 2009-11-26 2010-11-24 Novel naphthyridine derivatives and the use thereof as kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1170737A1 true HK1170737A1 (zh) 2013-03-08

Family

ID=41793139

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111592.5A HK1170737A1 (zh) 2009-11-26 2012-11-15 萘啶衍生物及其作為激酶抑制劑的用途

Country Status (19)

Country Link
US (1) US8461178B2 (zh)
EP (2) EP2332939A1 (zh)
JP (1) JP5726202B2 (zh)
KR (1) KR20120096545A (zh)
CN (1) CN102666536B (zh)
AR (1) AR079131A1 (zh)
AU (1) AU2010323137B2 (zh)
BR (1) BR112012012694A2 (zh)
CA (1) CA2781818A1 (zh)
ES (1) ES2573665T3 (zh)
HK (1) HK1170737A1 (zh)
IL (1) IL219646A0 (zh)
MX (1) MX345495B (zh)
NZ (1) NZ600042A (zh)
PL (1) PL2504336T3 (zh)
RU (1) RU2573390C2 (zh)
TW (1) TWI508963B (zh)
WO (1) WO2011064250A1 (zh)
ZA (1) ZA201202906B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP5792128B2 (ja) 2011-07-29 2015-10-07 富士フイルム株式会社 １，５−ナフチリジン誘導体又はその塩
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
CN103183674B (zh) * 2011-12-31 2017-09-12 江苏先声药业有限公司 一类稠杂环衍生物及其应用
TWI623536B (zh) * 2012-01-19 2018-05-11 腫瘤療法 科學股份有限公司 １,５－萘啶衍生物與含此之ｍｅｌｋ抑制劑
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014109414A1 (ja) 2013-01-11 2014-07-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
TWI715901B (zh) * 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3848034A1 (en) 2014-03-26 2021-07-14 Astex Therapeutics Limited Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN108137546B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
CA3010890C (en) * 2016-01-11 2023-09-26 Merck Patent Gmbh Quinolin-2-one derivatives
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN115806523A (zh) * 2022-11-24 2023-03-17 贵州医科大学 一种取代喹啉化合物及其在制备抗肿瘤药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2650826A1 (de) 1976-11-06 1978-05-11 Merck Patent Gmbh Cephemderivate
ES2146782T3 (es) * 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
AU4037799A (en) 1998-05-08 1999-11-29 Smithkline Beecham Plc Phenylurea and phenylthio urea derivatives
GB9822440D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
WO2000043383A1 (en) 1999-01-20 2000-07-27 Smithkline Beecham P.L.C. Piperidinylquinolines as protein tyrosine kinase inhibitors
ATE264328T1 (de) 1999-04-21 2004-04-15 Wyeth Corp Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
PL366335A1 (en) 2000-07-26 2005-01-24 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003290734A1 (en) * 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
US20090062294A1 (en) 2007-05-25 2009-03-05 Richard Apodaca Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
US8455648B2 (en) 2008-04-24 2013-06-04 Abbott Gmbh & Co. Kg 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)

Also Published As

Publication number Publication date
TW201121972A (en) 2011-07-01
ES2573665T3 (es) 2016-06-09
BR112012012694A2 (pt) 2019-09-24
RU2012120288A (ru) 2014-01-10
ZA201202906B (en) 2012-12-27
AU2010323137B2 (en) 2014-04-10
TWI508963B (zh) 2015-11-21
PL2504336T3 (pl) 2016-10-31
IL219646A0 (en) 2012-07-31
CN102666536B (zh) 2016-03-30
EP2504336A1 (en) 2012-10-03
US8461178B2 (en) 2013-06-11
MX345495B (es) 2017-02-02
EP2504336B1 (en) 2016-03-30
US20110150831A1 (en) 2011-06-23
JP5726202B2 (ja) 2015-05-27
CN102666536A (zh) 2012-09-12
JP2013512217A (ja) 2013-04-11
EP2332939A1 (en) 2011-06-15
WO2011064250A1 (en) 2011-06-03
AR079131A1 (es) 2011-12-28
CA2781818A1 (en) 2011-06-03
RU2573390C2 (ru) 2016-01-20
AU2010323137A1 (en) 2012-06-07
KR20120096545A (ko) 2012-08-30
MX2012006154A (es) 2012-06-28
NZ600042A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
HK1170737A1 (zh) 萘啶衍生物及其作為激酶抑制劑的用途
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
HK1219950A1 (zh) 作爲激酶抑制劑的吡咯並吡啶
HK1156026A1 (zh) 吡唑並吡啶激酶抑制劑
ZA201108622B (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
IL218555A0 (en) Pi3 kinase inhibitors and uses thereof
HK1179477A1 (zh) 激酶抑制劑
ZA201203842B (en) Kinase inhibitors
HUE052110T2 (hu) AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
ZA201204793B (en) Substituted naphthyridines and their use as syk kinase inhibitors
EP2558099A4 (en) Kinase Inhibitors
EP2563125A4 (en) AZAINDOLE AS JANUSKINASE HEMMER
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
HK1198646A1 (zh) 取代的咪唑並噠嗪類化合物及其用途
IL209840A0 (en) Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
IL208771A0 (en) Iminopyridine derivatives and use thereof
ZA201103964B (en) 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
ZA201300036B (en) Banzamide derivatives and their use as hsp90 inhibitors
EP2480076A4 (en) IMIDAZOTHIAZOLIC INHIBITORS OF KINASES
EP2432321A4 (en) THIAZOLOPYRIMIDINONE DERIVATIVES AS INHIBITORS OF PI3 KINASE
GB0914726D0 (en) Kinase inhibitors
ZA200907650B (en) Pyrrolopyridine derivatives and their use as bace inhibitors
EP2312948A4 (en) 5-CHINOLINONE AND IMIDAZOPYRIDINE COMPOUNDS AND THEIR USE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201122